(summarized due to limitation of characters)

        Inclusion Criteria:

          1. Written informed consent

          2. Aged at least 18 years (20 years for Japan)

          3. Histological or cytological confirmation diagnosis of EGFRm+ NSCLC. Confirmation from
             a previous archival sample that the tumour harbours an EGFRm+ known to be associated
             with EGFR TKI sensitivity.

          4. Radiological documentation of disease progression while on a previous continuous
             treatment with an EGFR TKI (on the last treatment administered prior to enrolling in
             the study)

             Part B cMET+ve patients:

               -  No prior treatment with a 3rd generation TKI: at least one prior line of therapy
                  with 1st or 2nd generation EGFR TKI, but not a 3rd generation (T790M-directed)
                  EGFR TKI.

               -  Prior treatment with a 3rd generation TKI: at least one prior line of therapy
                  with a 3rd generation (T790M-directed) EGFR TKI for EGFRm or T790M+ NSCLC.

             Part B cMET-ve patients:

               -  T790M directed EGFR TKI patients only: their immediate prior therapy before entry
                  into this study must be a T790M directed EGFR TKI.

               -  ≥2nd line cohort: patients must have progressed while on treatment with an EGFR
                  TKI (T790M directed EGFR TKIs are permitted). Other prior lines of therapy may
                  have been given.

             Part D cMET-ve patients:

             No prior treatment with a 3rd generation TKI, T790M negative:

             Patients must have received at least one prior line of therapy with 1st or 2nd
             generation EGFR TKI, but not a 3rd generation (T790M directed) EGFR TKI.

          5. cMET status: Prior to study entry, local confirmation of tumour cMET status is
             acceptable, a central result will be confirmed retrospectively. If a local test is not
             available, central confirmation of tumour cMET status must be obtained prior to study
             entry.

             T790M status: Local confirmation of tumour T790M status is acceptable, a central
             result will be confirmed retrospectively. If local testing is performed with the
             Cobas® EGFR Mutation Test, the central confirmation is not required.

          6. At least one lesion, not previously irradiated, not biopsied during the screening
             period, that can be accurately measured at baseline as ≥10 mm in the longest diameter
             (except lymph nodes which must have short axis ≥15 mm) with CT or MRI which is
             suitable for accurate repeated measurements

          7. WHO performance status 0-1 with no deterioration over the previous 2 weeks and minimum
             life expectancy of 12 weeks

          8. Females should be using adequate contraceptive measures, must not be breast feeding
             and must have a negative pregnancy test prior to start of dosing if of child-bearing
             potential or must have evidence of non-child-bearing potential.

        Exclusion Criteria (summary):

          -  Treatment with an EGFR TKI within approximately 5x half-life of the first dose of
             study treatment. Any cytotoxic chemotherapy, investigational agents or other
             anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen
             or clinical study within 14 days of the first dose of study treatment. Patients
             currently receiving (or unable to stop use) medications or herbal supplements known to
             be potent inducers of CYP3A4 (at least 3 weeks prior). For AZD6094 patients currently
             receiving (or unable to stop use at least 2 weeks) prior to receiving the first dose,
             medications known to be strong inhibitors of CYP1A2. Prior AZD9291 dosing in the
             present study. Prior or current treatment with AZD6094 or another cMET inhibitor (if
             allocated to AZD9291 + AZD6094). Radiotherapy with a limited field of radiation for
             palliation within 1 week of the first dose of study treatment, with the exception of
             patients receiving radiation to more than 30% of the bone marrow or with a wide field
             of radiation which must be completed within ≥4 weeks of the first dose of study
             treatment. Major (or anticipated major) surgical procedure (excluding placement of
             vascular access) or significant traumatic injury within 4 weeks of the first dose of
             study treatment. Currently receiving treatment with warfarin sodium.

          -  With the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy,
             any unresolved toxicities from prior therapy and/or pre-study biopsies greater than
             CTCAE Grade 1 at the time of starting study treatment.

          -  Spinal cord compression or brain metastases unless asymptomatic, stable and not
             requiring steroids for at least 2 weeks prior to start of study treatment.

          -  Severe or uncontrolled systemic diseases; known serious active infection; active
             hepatitis B or C; cardiac disease; inadequate bone marrow reserve or organ function or
             coagulation parameters; inadequate liver or renal function; GI events that would
             preclude adequate absorption, distribution, metabolism or excretion of AZD9291,
             AZD6094 or selumetinib; hipersensitivity to IP or similar drugs

          -  Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation
             pneumonitis which required steroid treatment, or any evidence of clinically active
             ILD.